Novel Protein Triggers Cancer Cell Death by Disrupting Iron Defense System
Researchers discover CCDC7₁₉₋₁₃ protein induces ferroptosis in prostate cancer by degrading protective SLC7A11.
Summary
Scientists identified a chimeric RNA called CCDC7₁₉₋₁₃ that produces a novel protein capable of killing prostate cancer cells through ferroptosis—a form of cell death driven by iron accumulation. The protein works by degrading SLC7A11, a key component of the cell's antioxidant defense system. Low levels of CCDC7₁₉₋₁₃ predict poor outcomes in prostate cancer patients, while restoring it suppresses tumor growth. The recombinant protein shows promise as a therapeutic agent, enhancing the effectiveness of existing cancer drugs without toxicity in preclinical models.
Detailed Summary
Prostate cancer remains a leading cause of cancer death in men, with treatment resistance and metastasis driving poor outcomes. This study reveals a promising new therapeutic target: a chimeric RNA called CCDC7₁₉₋₁₃ that encodes a tumor-suppressing protein.
Researchers analyzed 202 prostate cancer patients and found that CCDC7₁₉₋₁₃ expression is significantly reduced in advanced, recurrent, and metastatic cancers. Low expression levels independently predict poor prognosis, making this molecule a valuable biomarker for disease progression.
The team discovered that CCDC7₁₉₋₁₃ produces a 241-amino acid protein (CCDC7₂₄₁ₐₐ) that triggers ferroptosis—a regulated form of cell death caused by iron accumulation and lipid damage. This protein works by binding to SLC7A11, a crucial component of the cell's antioxidant defense system, and facilitating its degradation through TRIM21-mediated ubiquitination. Without SLC7A11, cancer cells become vulnerable to oxidative damage and die.
Functional studies demonstrated that overexpressing CCDC7₁₉₋₁₃ inhibits cell proliferation, induces apoptosis, and suppresses tumor growth in laboratory models. Conversely, reducing its expression promotes cancer progression. Importantly, treatment with recombinant CCDC7₂₄₁ₐₐ protein effectively suppressed tumor growth in patient-derived xenograft models without causing toxicity.
The therapeutic potential extends beyond monotherapy. The recombinant protein enhanced the effectiveness of standard treatments like docetaxel and enzalutamide in laboratory studies, suggesting potential for combination therapies. This approach could be particularly valuable for treatment-resistant prostate cancers, which often evade conventional therapies but may remain vulnerable to ferroptosis-inducing agents.
Key Findings
- CCDC7₁₉₋₁₃ expression is reduced in advanced prostate cancer and predicts poor prognosis
- The encoded CCDC7₂₄₁ₐₐ protein induces ferroptosis by degrading SLC7A11 via TRIM21-mediated ubiquitination
- Recombinant CCDC7₂₄₁ₐₐ suppresses tumor growth without toxicity in patient-derived models
- The protein enhances efficacy of docetaxel and enzalutamide in combination therapy
- Overexpression inhibits proliferation while knockdown promotes cancer progression
Methodology
Study analyzed 202 prostate cancer patients across multiple cohorts, used patient-derived xenograft models, and employed comprehensive molecular techniques including RNA sequencing, protein interaction assays, and functional studies in multiple cell lines.
Study Limitations
Study focused primarily on prostate cancer with limited exploration in other cancer types. Long-term safety and efficacy of recombinant protein therapy require clinical validation. Optimal dosing and delivery methods need further investigation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.